drugset
Drugs / NXP800
last change Dec 2025 re-read 3 minutes ago

NXP800

Small molecule

Developed for
hilar cholangiocarcinoma · ovarian clear cell adenocarcinoma · ovarian endometrioid adenocarcinoma
Investigated by
European Network of Gynaecological Oncological Trial Groups (ENGOT) · Gynecologic Oncology Group Foundation · Mayo Clinic · Nuvectis Pharma, Inc.

Trials 2

today NCT06420349 · Ph 1 NCT05226507 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06420349 May 2024 → Aug 2025 hilar cholangiocarcinoma Mayo Clinic Terminated No outcome recorded
Phase 1 NCT05226507 Dec 2021 → Dec 2025 overdue ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma Nuvectis Pharma, Inc. Active not recruiting No outcome recorded

Press releases naming this drug 17 releases

DateIssuerRelease
2025-07-31 Nuvectis Pharma, Inc. Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study nuvectis.com ↗
2024-11-14 Nuvectis Pharma, Inc. Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer nuvectis.com ↗
2024-08-29 Nuvectis Pharma, Inc. Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers nuvectis.com ↗
2024-03-14 Nuvectis Pharma, Inc. Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer nuvectis.com ↗
2023-12-18 Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma nuvectis.com ↗
2023-10-24 Nuvectis Pharma, Inc. Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer nuvectis.com ↗
2023-09-21 Nuvectis Pharma, Inc. Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 nuvectis.com ↗
2023-09-06 Nuvectis Pharma, Inc. Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 nuvectis.com ↗
2023-08-17 Nuvectis Pharma, Inc. Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma nuvectis.com ↗
2023-04-18 Nuvectis Pharma, Inc. Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research ("AACR") Annual Meeting nuvectis.com ↗
2023-04-10 Nuvectis Pharma, Inc. Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma nuvectis.com ↗
2023-02-23 Nuvectis Pharma, Inc. Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress nuvectis.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as NXP800 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06420349 ↗
1

NCT05226507 ↗
Action Inhibit “NXP800 inhibits a pathway called the heat shock factor 1 (HSF1) pathway.” NCT06420349 ↗
Modality Small molecule “NXP800 is an anti-neoplastic, oral small molecule.” NCT05226507 ↗
Route Oral “Escalating doses of NXP800 administered orally once or twice daily.” NCT05226507 ↗